Repare Therapeutics Inc.
RPTX
$1.43
$0.010.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 1.07M | 52.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 1.07M | 52.40M |
| Cost of Revenue | 20.27M | -78.07M | 28.40M | 30.08M | 32.97M |
| Gross Profit | -20.27M | 78.07M | -28.40M | -29.00M | 19.43M |
| SG&A Expenses | 7.65M | 8.84M | 6.44M | 8.32M | 8.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.92M | 30.80M | 34.85M | 38.39M | 41.59M |
| Operating Income | -27.92M | -30.80M | -34.85M | -37.32M | 10.82M |
| Income Before Tax | -29.67M | -28.67M | -33.92M | -34.45M | 13.79M |
| Income Tax Expenses | 370.00K | 0.00 | 485.00K | 326.00K | 629.00K |
| Earnings from Continuing Operations | -30.04M | -28.67M | -34.41M | -34.77M | 13.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.04M | -28.67M | -34.41M | -34.77M | 13.16M |
| EBIT | -27.92M | -30.80M | -34.85M | -37.32M | 10.82M |
| EBITDA | -26.74M | -30.34M | -34.37M | -36.83M | 11.32M |
| EPS Basic | -0.71 | -0.67 | -0.81 | -0.82 | 0.31 |
| Normalized Basic EPS | -0.39 | -0.42 | -0.48 | -0.51 | 0.20 |
| EPS Diluted | -0.71 | -0.67 | -0.81 | -0.82 | 0.30 |
| Normalized Diluted EPS | -0.39 | -0.42 | -0.48 | -0.51 | 0.20 |
| Average Basic Shares Outstanding | 42.59M | 42.51M | 42.45M | 42.45M | 42.23M |
| Average Diluted Shares Outstanding | 42.59M | 42.51M | 42.45M | 42.45M | 44.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |